



## 104TH GENERAL ASSEMBLY

### State of Illinois

2025 and 2026

SB1258

Introduced 1/28/2025, by Sen. Graciela Guzmán

#### SYNOPSIS AS INTRODUCED:

215 ILCS 200/52 new

Amends the Prior Authorization Reform Act. Provides that a health insurance issuer may not require prior authorization for: a prescription drug prescribed to a patient by a health care professional for 6 or more consecutive months, regardless of whether the prescription drug is a non-preferred medication pursuant to the patient's health insurance coverage; the following prescription drugs or the therapeutic equivalent approved by the United States Food and Drug Administration: insulin; human immunodeficiency virus prevention medication; human immunodeficiency virus treatment medication; viral hepatitis medication; estrogen; and progesterone; or human immunodeficiency virus pre-exposure prophylaxis and post-exposure prophylaxis drugs approved by the United States Food and Drug Administration; Truvada; Harvoni; Descovy; and Apretude.

LRB104 08130 BAB 18176 b

1 AN ACT concerning regulation.

2 **Be it enacted by the People of the State of Illinois,**  
3 **represented in the General Assembly:**

4 Section 5. The Prior Authorization Reform Act is amended  
5 by adding Section 52 as follows:

6 (215 ILCS 200/52 new)

7 Sec. 52. Prior authorization prohibited. A health  
8 insurance issuer may not require prior authorization for:

9 (1) a prescription drug prescribed to a patient by a  
10 health care professional for 6 or more consecutive months,  
11 regardless of whether the prescription drug is a  
12 non-preferred medication pursuant to the patient's health  
13 insurance coverage;

14 (2) the following prescription drugs or the  
15 therapeutic equivalent approved by the United States Food  
16 and Drug Administration: insulin; human immunodeficiency  
17 virus prevention medication; human immunodeficiency virus  
18 treatment medication; viral hepatitis medication;  
19 estrogen; and progesterone; or

20 (3) human immunodeficiency virus pre-exposure  
21 prophylaxis and post-exposure prophylaxis drugs approved  
22 by the United States Food and Drug Administration;  
23 Truvada; Harvoni; Descovy; and Apretude.